TECH BIO-TECHNE Corp
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 842023 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.9%
TTM net income YoY120.5%
TTM EPS YoY124.5%
Revenue 3-yr CAGR2.4%
Net income 3-yr CAGR-11.3%
Margins
Gross margin65.8%
Operating margin19.6%
Net margin14.0%
FCF margin25.1%
EBITDA margin27.5%
Returns
ROE8.3%
ROA6.7%
ROIC (approx.)9.3%
Asset turnover0.48x
Leverage & solvency
Liabilities / assets17.9%
Debt / equity0.00x
Current ratio2.28x
Interest coverage27.16x
Cash quality & payout
Operating cash flow / net income1.96x
Accruals ratio-6.4%
Payout ratio29.1%
Capex / revenue2.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2026*2026-06-30 | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.22B | $1.22B | $1.16B | $1.14B | $1.11B |
| Cost of revenue | $415.97M | $429.36M | $389.33M | $366.89M | $349.10M |
| Gross profit | $799.07M | $790.27M | $769.73M | $769.82M | $756.50M |
| R&D expense | $94.77M | $99.50M | $96.66M | $92.49M | $87.14M |
| SG&A expense | $452.42M | $588.52M | $466.38M | $378.38M | $372.77M |
| Operating income | $251.89M | $102.25M | $206.69M | $298.94M | $296.59M |
| Interest expense | $9.63M | $8.51M | $15.74M | $11.21M | $11.31M |
| Pretax income | $240.68M | $98.46M | $185.69M | $338.66M | $301.39M |
| Income tax | $58.82M | $25.06M | $17.58M | $53.22M | $38.29M |
| Net income | $181.86M | $73.40M | $168.10M | $285.26M | $272.05M |
| EBITDA | $349.25M | $212.16M | $318.40M | $406.18M | $397.66M |
| EPS (basic) | 1.17 | 0.47 | 1.07 | 1.81 | 1.73 |
| EPS (diluted) | 1.16 | 0.46 | 1.05 | 1.76 | 1.66 |
| Dividends declared per share | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 |
| Weighted avg. shares (diluted) | 157.01M | 159.72M | 160.77M | 161.85M | 164.11M |
| Balance sheet | |||||
| Cash & equivalents | $264.71M | $162.19M | $151.79M | $180.57M | $172.57M |
| Short-term investments | — | — | $1.07M | $23.74M | $74.46M |
| Receivables | $216.59M | $206.88M | $241.39M | $218.47M | $194.55M |
| Inventory | $195.74M | $189.45M | $179.73M | $171.64M | $141.12M |
| Current assets | $744.40M | $608.30M | $617.42M | $621.48M | $605.56M |
| PP&E, net | $231.84M | $245.72M | $251.15M | $226.20M | $223.24M |
| Goodwill | $975.36M | $980.93M | $972.66M | $872.74M | $822.10M |
| Intangibles | $303.46M | $365.60M | $507.08M | $534.64M | $531.52M |
| Total assets | $2.59B | $2.56B | $2.70B | $2.64B | $2.29B |
| Current liabilities | $163.70M | $175.85M | $159.38M | $128.51M | $176.02M |
| Short-term debt | — | — | — | — | $12.50M |
| Long-term debt | $200.00M | $346.00M | $319.00M | $350.00M | $243.41M |
| Total debt | $200.00M | $346.00M | $319.00M | $350.00M | $255.91M |
| Total liabilities | $478.50M | $639.06M | $635.02M | $672.18M | $593.79M |
| Shareholders' equity | $2.11B | $1.92B | $2.07B | $1.97B | $1.70B |
| Net debt | -$64.71M | $183.81M | $167.21M | $169.43M | $83.34M |
| Shares outstanding | 156.10M | 154.97M | 158.22M | 157.64M | 156.64M |
| Cash flow statement | |||||
| Operating cash flow | $292.07M | $287.56M | $298.98M | $254.39M | $325.27M |
| Capital expenditure | $28.85M | $31.01M | $62.88M | $38.24M | $44.91M |
| Free cash flow | $263.22M | $256.55M | $236.10M | $216.15M | $280.36M |
| Investing cash flow | -$18.19M | -$35.18M | -$203.03M | -$265.65M | -$96.85M |
| Financing cash flow | -$169.11M | -$253.91M | -$122.40M | $22.62M | -$242.85M |
| Depreciation & amortization | $97.36M | $109.90M | $111.71M | $107.24M | $101.07M |
| Stock-based compensation | $41.37M | $40.83M | $38.04M | $39.23M | $42.18M |
| Dividends paid | $49.92M | $50.39M | $50.42M | $50.28M | $50.19M |
| Share buybacks | $41.67M | $275.73M | $80.04M | $19.56M | $160.95M |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.